Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for IDEAYA Biosciences (IDYA) over the last 5 years, with Mar 2025 value amounting to $6.2 million.

  • IDEAYA Biosciences' Gains from Investment Securities fell 57.34% to $6.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $23.7 million, marking a year-over-year decrease of 23.10%. This contributed to the annual value of $32.0 million for FY2024, which is 89.35% up from last year.
  • IDEAYA Biosciences' Gains from Investment Securities amounted to $6.2 million in Q1 2025, which was up 286.62% from $1.6 million recorded in Q4 2024.
  • IDEAYA Biosciences' Gains from Investment Securities' 5-year high stood at $14.5 million during Q1 2024, with a 5-year trough of -$2.4 million in Q4 2021.
  • Over the past 3 years, IDEAYA Biosciences' median Gains from Investment Securities value was $3.4 million (recorded in 2024), while the average stood at $6.1 million.
  • The largest annual percentage gain for IDEAYA Biosciences' Gains from Investment Securities in the last 5 years was 15,100.00% (2021), contrasted with its biggest fall of 1,046.41% (2021).
  • Over the past 5 years, IDEAYA Biosciences' Gains from Investment Securities (Quarterly) stood at -$2.4 million in 2021, then skyrocketed by 125.04% to $600,000 in 2022, then spiked by 2,050.00% to $12.9 million in 2023, then plummeted by 87.60% to $1.6 million in 2024, then tumbled by 57.34% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q1 2025, $1.6 million for Q4 2024, and $3.4 million during Q3 2024.